MAP855
oral MEK1/2 inhibitor Preclinical, oncology from HTS and SBDD J. Med. Chem. Novartis Institutes for BioMedical Research
Molecules of the Month - February 2022
oral MEK1/2 inhibitor Preclinical, oncology from HTS and SBDD J. Med. Chem. Novartis Institutes for BioMedical Research
Molecules of the Month - February 2022